Imunon Targets ~80 OVATION 3 Patients in 12 Months, Cash Runway Extends to H2 2026

Imunon has set a critical operational target for its OVATION 3 clinical trial, aiming to enroll approximately 80 patients over the next 12 months. This aggressive enrollment goal comes as the company reports a significant extension of its financial runway, now projected to last into the second half of 2026. The dual announcement signals a period of focused execution, where the company's near-term clinical progress is directly tied to its secured capital.

The OVATION 3 trial is a central component of Imunon's clinical pipeline. The patient enrollment target represents a concrete, measurable milestone for the coming year, providing a clear benchmark for investors and stakeholders to monitor. The extended cash runway, reaching into H2 2026, alleviates immediate financial pressure and provides the operational stability required to pursue this ambitious patient recruitment goal without the near-term distraction of fundraising.

This development places Imunon in a position where clinical execution becomes the paramount driver of value. The extended financial cushion allows management to concentrate resources on trial site activation, patient screening, and data collection. Success in meeting the ~80-patient target within the specified timeframe will be a key indicator of the trial's operational viability and could significantly influence the company's valuation and partnership prospects as it advances its therapeutic candidates.